Evaluating Serum Beta-2-Microglobulin Levels for Uremic Pericarditis Risk in End-Stage Renal Disease Patients.

IF 0.7 4区医学 Q4 MEDICAL LABORATORY TECHNOLOGY

Clinical laboratory Pub Date : 2025-06-01 DOI:10.7754/Clin.Lab.2024.240903

Jing J Zhang, Shui X Wang, Lei Zhang

{"title":"Evaluating Serum Beta-2-Microglobulin Levels for Uremic Pericarditis Risk in End-Stage Renal Disease Patients.","authors":"Jing J Zhang, Shui X Wang, Lei Zhang","doi":"10.7754/Clin.Lab.2024.240903","DOIUrl":null,"url":null,"abstract":"Background: The aim of this study was to investigate the clinical significance of serum β-2-microglobulin (B2M) in predicting the development of uremic pericarditis (UP) in patients with end-stage renal disease (ESRD).Methods: Three hundred ESRD patients who started hemodialysis and underwent echocardiography were selected. The clinical data of 300 ESRD patients were obtained through the hospital medical record system. Serum B2M levels were measured 24 hours before starting hemodialysis. Risk factors for the occurrence of UP in ESRD patients were analyzed by logistic regression. Predictive value of serum B2M levels for the development of UP in ESRD patients was analyzed by ROC curve.Results: Twenty-eight out of 300 ESRD patients developed UP. Serum B2M levels were higher in ESRD patients with UP. Higher serum B2M level was a risk factor for UP in ESRD patients. Serum B2M levels had a high predictive value for the development of UP in ESRD patients.Conclusions: Serum B2M levels have a high predictive value for the development of UP in ESRD patients, and high serum B2M levels are associated with UP risk.","PeriodicalId":10384,"journal":{"name":"Clinical laboratory","volume":"71 6","pages":""},"PeriodicalIF":0.7000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical laboratory","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.7754/Clin.Lab.2024.240903","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The aim of this study was to investigate the clinical significance of serum β-2-microglobulin (B2M) in predicting the development of uremic pericarditis (UP) in patients with end-stage renal disease (ESRD).

Methods: Three hundred ESRD patients who started hemodialysis and underwent echocardiography were selected. The clinical data of 300 ESRD patients were obtained through the hospital medical record system. Serum B2M levels were measured 24 hours before starting hemodialysis. Risk factors for the occurrence of UP in ESRD patients were analyzed by logistic regression. Predictive value of serum B2M levels for the development of UP in ESRD patients was analyzed by ROC curve.

Results: Twenty-eight out of 300 ESRD patients developed UP. Serum B2M levels were higher in ESRD patients with UP. Higher serum B2M level was a risk factor for UP in ESRD patients. Serum B2M levels had a high predictive value for the development of UP in ESRD patients.

Conclusions: Serum B2M levels have a high predictive value for the development of UP in ESRD patients, and high serum B2M levels are associated with UP risk.

查看原文本刊更多论文

评估终末期肾病患者尿毒症心包炎风险的血清β -2微球蛋白水平

背景：本研究旨在探讨血清β-2微球蛋白（B2M）在预测终末期肾病（ESRD）患者尿毒症性心包炎（UP）发展中的临床意义。方法：选取开始血液透析并行超声心动图检查的ESRD患者300例。通过医院病案系统获取300例ESRD患者的临床资料。开始血液透析前24小时测定血清B2M水平。采用logistic回归分析ESRD患者UP发生的危险因素。采用ROC曲线分析血清B2M水平对ESRD患者UP发展的预测价值。结果：300例ESRD患者中有28例发生UP。ESRD合并UP患者血清B2M水平较高。较高的血清B2M水平是ESRD患者UP的危险因素。血清B2M水平对ESRD患者UP的发展具有较高的预测价值。结论：血清B2M水平对ESRD患者UP的发展具有较高的预测价值，高血清B2M水平与UP风险相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical laboratory 医学-医学实验技术

CiteScore

1.50

自引率

0.00%

发文量

494

审稿时长

3 months

期刊介绍： Clinical Laboratory is an international fully peer-reviewed journal covering all aspects of laboratory medicine and transfusion medicine. In addition to transfusion medicine topics Clinical Laboratory represents submissions concerning tissue transplantation and hematopoietic, cellular and gene therapies. The journal publishes original articles, review articles, posters, short reports, case studies and letters to the editor dealing with 1) the scientific background, implementation and diagnostic significance of laboratory methods employed in hospitals, blood banks and physicians'' offices and with 2) scientific, administrative and clinical aspects of transfusion medicine and 3) in addition to transfusion medicine topics Clinical Laboratory represents submissions concerning tissue transplantation and hematopoietic, cellular and gene therapies.